We are searching data for your request:
Upon completion, a link will appear to access the found materials.
APOSEC: biological active pharmaceutical ingredient enables new therapy for skin wounds
Austrian researchers discovered a few years ago that APOSEC, a substance derived from white blood cells, can contribute to improved regeneration after heart attacks. This drug ingredient apparently also enables new forms of therapy for skin wounds.
White blood cell substance
In the case of smaller wounds, it is usually sufficient to stick a plaster on it or to ensure faster wound healing with simple home remedies. With chronic wounds you don't get very far. In such cases APOSEC could help in the future. It is a substance obtained from white blood cells that was developed by a team of scientists from Austria. The promising active ingredient is currently in the clinical phase of the approval process for a new drug for external wound healing.
Newly developed drug ingredient
Before a newly developed active pharmaceutical ingredient is used, it has to go through a lengthy approval procedure.
So also the biological substance APOSEC developed and patented by Hendrik Jan Ankersmit and his team at the MedUni Vienna, which consists of soluble proteins, exosomes and lipids from white blood cells, as it is stated in a message.
These must first be irradiated and release proteins, a “secretome”, during cell death. This has multiple therapeutic efficacies, as the research team has already shown in preclinical trials.
Among other things, it has an antibacterial effect, induces the formation of new vessels and activates wound healing.
The cells (white blood cells) can thus be understood as a “bioreactor” which secretes the secretoma - the cellular component is discarded in a test tube after a culture period.
The therapeutic effect comes solely from the variety of secreted ingredients.
Wide range of uses
In the current clinical phase 1, human APOSEC, manufactured under GMP (Good Manufacturing Practice) conditions, is used, which has been released for clinical testing on humans by the AGES (Austrian Agency for Food Security).
The associated study Marsyas-1 is the world's first secretome-based skin regeneration study and has now been published in "Nature Scientific Reports".
The aim of the study to demonstrate the safety of the active substance in dermatological wounds was achieved. The blood cells required for this were obtained autologously, that is, from the test subjects' own material.
The research team is now working on the production of APOSEC from allogeneic cell material, i.e. that from external donors.
In this way, inexpensive production in large quantities would be possible and the drug could be available in the freeze-dried state for immediate use.
Based on the research results to date, APOSEC promises a wide range of uses, including for heart attacks, myocarditis, stroke and spinal cord injuries. (ad)